Roivant Sciences (ROIV) Income from Non-Controlling Interests (2020 - 2025)
Roivant Sciences (ROIV) posted Income from Non-Controlling Interests of -$150.9 million for Q4 2025, down 187.29% on a QoQ basis from -$52.5 million in Q3 2025, and down 8.67% year-over-year from -$165.2 million in Q4 2024.
Roivant Sciences (ROIV) Income from Non-Controlling Interests (2020 - 2025) Analysis & Trends
Roivant Sciences' Income from Non-Controlling Interests history runs 6 years deep, the most recent figure standing at -$150.9 million for Q4 2025.
- Quarterly Income from Non-Controlling Interests fell 8.67% year-over-year to -$150.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$392.8 million (down 25.6% YoY) and the FY2026 annual result came in at -$98.1 million, up 46.88% from the prior year.
- Income from Non-Controlling Interests was -$150.9 million for Q4 2025 at Roivant Sciences, down from -$52.5 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at -$17.2 million in Q3 2021 and bottomed at -$150.9 million in Q4 2025.
- A 5-year average of -$56.6 million and a median of -$49.7 million in 2024 frame the typical range for Income from Non-Controlling Interests.
- Peak annual rise in Income from Non-Controlling Interests reached 5.2% in 2021, while the deepest fall reached 299.13% in 2021.
- Roivant Sciences' Income from Non-Controlling Interests stood at -$57.6 million in 2021, then slumped by 37.47% to -$79.2 million in 2022, then fell by 9.03% to -$86.3 million in 2023, then sank by 60.82% to -$138.9 million in 2024, then retreated by 8.67% to -$150.9 million in 2025.
- Business Quant data shows ROIV's Income from Non-Controlling Interests at -$150.9 million in Q4 2025, -$52.5 million in Q3 2025, and -$50.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Roivant Sciences | 24.27 Bn | 24.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -150.89 Mn |
| Sep 30, 2025 | -52.52 Mn |
| Jun 30, 2025 | -50.56 Mn |
| Dec 31, 2024 | -138.85 Mn |
| Sep 30, 2024 | -49.74 Mn |
| Jun 30, 2024 | -37.81 Mn |
| Dec 31, 2023 | -86.34 Mn |
| Sep 30, 2023 | -26.79 Mn |
| Jun 30, 2023 | -36.03 Mn |
| Dec 31, 2022 | -79.19 Mn |
| Sep 30, 2022 | -24.33 Mn |
| Jun 30, 2022 | -21.98 Mn |
| Dec 31, 2021 | -57.60 Mn |
| Sep 30, 2021 | -17.16 Mn |
| Jun 30, 2021 | -18.90 Mn |
| Dec 31, 2020 | -14.57 Mn |
| Sep 30, 2020 | -18.10 Mn |
| Jun 30, 2020 | -4.73 Mn |